publication date: May. 30, 2014


By Paul Goldberg

Moffitt Cancer Center and the Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute earlier this week announced that they are constructing a bioinformatics framework that would enable a multi-center collaboration.

The network, called the Oncology Research Information Exchange Network, or ORIEN, is seeking to form partnerships with other leading cancer centers in North America.

ORIEN has over 100,000 consented patients who have agreed to donate tissue and clinical data. The network will use a single protocol, Total Cancer Care, to create a collaborative, “rapid learning” environment that will share de-identified data to accelerate the development of targeted treatments.

The two founding centers said theirs is likely the largest collaboration of its kind to accelerate discoveries in cancer research. Financial details of the collaboration and the terms on which other centers can join were not disclosed.

“If we can bring on a couple of centers a year, that would be good,” said Dan Sullivan, associate center director for clinical sciences at Moffitt, chief medical officer of M2Gen, a subsidiary of Moffitt that will serve as ORIEN’s operational and commercial provider for data management and informatics. “We’ve had interest expressed by probably 10 to 15 different sites.”

The network is one of the arrangements that has emerged recently, as institutions are vying to identify patients with mutations—frequently rare mutations—that are becoming increasingly important in determining cancer care and running clinical trials.

“With ORIEN, we are amassing a true national cancer database for the first time,” Michael Caligiuri, … Continue reading 40-22 Moffitt, Ohio State Form Network, Invite Major Cancer Centers to Join

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.